ocugen
provides
business
update
third
quarter
financial
results
malvern
globe
newswire
ocugen
nasdaq
ocgn
biopharmaceutical
company
focused
discovering
developing
commercializing
transformative
therapies
cure
blindness
diseases
today
reported
third
quarter
financial
results
along
general
business
update
proud
advancements
made
quarter
developing
modifier
gene
therapy
novel
biologic
product
candidates
remain
achieve
multiple
near
milestones
plan
initiate
four
phase
trials
additionally
pleased
raised
approximately
million
gross
proceeds
extended
cash
runway
continued
development
product
candidates
said
shankar
musunuri
chairman
chief
executive
officer
ocugen
business
highlights
steady
progress
towards
starting
clinical
trials
ocugen
received
materials
good
laboratory
practice
glp
toxicology
study
manufacturing
partner
cansino
biologics
ocugen
commenced
detailed
design
two
parallel
phase
trials
target
commence
manufacturing
contract
october
ocugen
entered
agreement
kemwell
biopharma
pvt
ltd
kemwell
manufacture
ocugen
biologic
product
candidate
kemwell
offers
proven
expertise
supporting
companies
process
development
clinical
commercial
manufacturing
biologicals
agreement
kemwell
fundamental
step
enter
clinic
first
half
full
repayment
unsecured
notes
july
october
ocugen
made
aggregate
prepayments
million
unsecured
notes
associated
april
amendment
exchange
series
warrants
following
october
prepayments
unsecured
notes
repaid
full
longer
outstanding
capital
raised
third
quarter
ocugen
sold
aggregate
million
shares
common
stock
offering
commenced
august
generating
net
proceeds
million
increasing
cash
runway
third
quarter
third
quarter
financial
results
ocugen
cash
cash
equivalents
restricted
cash
totaled
million
september
compared
million
december
company
million
shares
common
stock
outstanding
september
research
development
expenses
three
months
ended
september
million
compared
million
three
months
ended
september
general
administrative
expenses
three
months
ended
september
million
compared
million
three
months
ended
september
ocugen
reported
loss
per
share
three
months
ended
september
compared
loss
per
share
three
months
ended
september
ocugen
ocugen
biopharmaceutical
company
focused
discovering
developing
commercializing
transformative
therapies
cure
blindness
diseases
breakthrough
modifier
gene
therapy
platform
potential
treat
multiple
retinal
diseases
one
drug
one
many
novel
biologic
product
candidate
aims
offer
better
therapy
patients
underserved
diseases
wet
macular
degeneration
diabetic
macular
edema
diabetic
retinopathy
information
please
visit
cautionary
note
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
subject
risks
uncertainties
may
cases
use
terms
predicts
believes
potential
proposed
continue
estimates
anticipates
expects
plans
intends
may
could
might
words
convey
uncertainty
future
events
outcomes
identify
statements
statements
subject
numerous
important
factors
risks
uncertainties
may
cause
actual
events
results
differ
materially
current
expectations
risks
uncertainties
fully
described
periodic
filings
securities
exchange
commission
sec
including
risk
factors
described
section
entitled
risk
factors
quarterly
annual
reports
file
sec
statements
make
press
release
speak
date
press
release
except
required
law
assume
obligation
update
statements
contained
press
release
whether
result
new
information
future
events
otherwise
date
press
release
corporate
contact
ocugen
sanjay
subramanian
chief
financial
officer
ir
media
contact
lavoiehealthscience
katie
gallagher
kgallagher
tables
follow
ocugen
consolidated
balance
sheets
unaudited
september
december
assets
current
assets
cash
cash
equivalents
prepaid
expenses
current
assets
asset
held
sale
total
current
assets
property
equipment
net
restricted
cash
assets
total
assets
liabilities
stockholders
equity
current
liabilities
accounts
payable
accrued
expenses
debt
net
operating
lease
obligation
current
liabilities
total
current
liabilities
liabilities
operating
lease
obligation
less
current
portion
long
term
debt
net
liabilities
total
liabilities
stockholders
equity
common
stock
treasury
stock
additional
capital
accumulated
deficit
total
stockholders
equity
total
liabilities
stockholders
equity
ocugen
consolidated
statements
operations
unaudited
